Pharmaceutical product valuation needs assumptions that include market share, compliance and diagnosis rates. These need to ...
While celebrating the near half-trillion dollars in US savings achieved by using generics and biosimilars in 2025, the AAM’s ...
Glenmark's Ryaltris has reached Brazil ahead of schedule, bringing the allergy nasal spray to what the firm describes as the ...
AstraZeneca and Daiichi Sankyo’s HER2-targeting ADC showed a PFS benefit in first-line treatment of HER2-mutant non-small ...
Medicare has finalized expanded coverage for TAVR, including certain asymptomatic patients with severe aortic stenosis, while ...
Strong PFS data and oral convenience may enable zipalertinib to compete against J&J’s bispecific Rybrevant in NSCLC patients ...
The company’s next move will depend on whether subgroup signals can survive a confirmatory trial.
The US FDA approved the myostatin inhibitor Isembyld (apitegromab) on top of SMN-targeted therapies for spinal muscular ...
Sanofi will transition 20 mature medicines to German established products player Cheplapharm, including the off-patent blood ...
VDGH chief executive Martin Walger is putting his hopes on positive EU trilog outcomes regarding the IVDR and MDR amendments, ...
Peerbridge plans to introduce its newly FDA-cleared second-generation Cor MDx patch for detecting heart arrythmias to health ...
The CDC’s decision to leave guidance unchanged ahead of the influenza season generates more questions than answers for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results